Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This action reduces the proliferation of rapidly dividing cells, such as immune cells involved in inflammation and cancer cells, while also promoting anti‑inflammatory pathways mediated by adenosine.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified healthcare professional can determine the appropriate dosing regimen, and patients should follow the prescribed instructions exactly.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated during pregnancy and women of child‑bearing potential must use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided while nursing.

To request Metoject, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Metoject (methotrexate) is a conventional synthetic DMARD and is often the first‑line disease‑modifying therapy for rheumatoid arthritis. Compared with biologic agents such as TNF‑α inhibitors, methotrexate is less expensive and administered subcutaneously, but biologics may be chosen when patients have an inadequate response or intolerance to methotrexate.

Metoject should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours.

Metoject is supplied as a sterile solution for subcutaneous injection. A healthcare professional or trained patient can inject the prescribed volume into the subcutaneous tissue of the abdomen, thigh or upper arm using an appropriate needle. Injection technique and site rotation are important to minimize local reactions.

The most serious risks include severe liver toxicity, life‑threatening bone‑marrow suppression, pulmonary fibrosis, renal failure and teratogenic effects. Patients should be monitored regularly for liver enzymes, blood counts and renal function, and any signs of infection, respiratory difficulty or unexplained bruising must be reported immediately.

Metoject is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, significant renal impairment (creatinine clearance < 30 mL/min), and patients with known hypersensitivity to methotrexate or any component of the formulation. It should also be avoided in patients receiving certain interacting medications without close supervision.